Abdel-Rahman Omar, Fouad Mona
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Future Oncol. 2015;11(8):1275-90. doi: 10.2217/fon.14.302.
In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs).
Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response.
In total, 16 trials including 348 patients were included. Median progression-free survival ranged from 6 to 31 months. The disease control rate ranged from 65 to 100%. Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases.
The published clinical data suggest that TMZ-based combination with some anticancer agents (especially capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.
在本系统评价中，我们探讨了使用基于替莫唑胺（TMZ）的联合方案治疗晚期神经内分泌肿瘤（NENs）的价值。
使用术语“NENs”、“TMZ”和“全身治疗”进行数据库检索。感兴趣的结果包括无进展生存期和总生存期、毒性和肿瘤反应。
共纳入16项试验，包括348例患者。中位无进展生存期为6至31个月。疾病控制率为65%至100%。常见的3/4级毒性反应为白细胞减少、淋巴细胞减少和转氨酶升高。
已发表的临床数据表明，基于TMZ联合某些抗癌药物（尤其是卡培他滨）可能是晚期低中级NENs的有效治疗选择。
